Cambium Bio (ASX:CMB) Cash Payments: A$-5.16 Mil (TTM As of Dec. 2025)


ASX:CMB Cambium Bio Ltd ASX:CMB
35 GF Score
Price A$0.41
! 4 Warning Signs
View Full Analysis

What is Cambium Bio Cash Payments?

Cambium Bio ASX:CMB 35 Cash Payments is A$-5.16 Mil as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review.

Cambium Bio's Cash Payments for the six months ended in Dec. 2025 was A$-2.18 Mil.

Cambium Bio's Cash Payments for the trailing twelve months (TTM) ended in Dec. 2025 was A$-5.16 Mil.

Cambium Bio Cash Payments Historical Data

* Premium members only.

The historical data trend for Cambium Bio's Cash Payments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio Cash Payments Chart

Cambium Bio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash Payments
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.52 -4.40 -1.76 -0.63 -5.94

Cambium Bio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Payments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -0.30 -2.96 -2.98 -2.18
ASX:CMB
35GF Score
Cambium Bio Ltd ASX:CMB
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio Cash Payments Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Cash Payments represents cash flow paid from operating activities in the direct cash flow method.

GuruFocus lists following items in "Cash Payments" section for non-financial companies:
Payments to Suppliers for Goods and Services
Payments on Behalf of Employees
Other Cash Payments from Operating Activities

Cash Payments for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-5.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Payments →
What does a Cash Payments of A$-5.16 Mil mean?
Cambium Bio (ASX:CMB) has a Cash Payments of A$-5.16 Mil as of Dec. 2025. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for Cambium Bio and its competitors.
Is Cambium Bio's Cash Payments too high?
Cambium Bio's current Cash Payments is A$-5.16 Mil. Overall, Cambium Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Cash Payments compare to VRTX and REGN?
Cambium Bio's Cash Payments of A$-5.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Payments for a Biotechnology company?
A good Cash Payments depends on the Biotechnology industry context. However, Cash Payments should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Payments mean?
A high Cash Payments can signal that a stock is expensive relative to its fundamentals. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for Cambium Bio and its competitors. Cambium Bio's current Cash Payments is A$-5.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Cash Payments of A$-5.16 Mil. The current Cash Payments is A$-5.16 Mil. Cambium Bio's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Payments calculated?
Cash Payments is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Cash Payments is A$-5.16 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
35GF Score

Get the complete analysis for ASX:CMB

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.41
Price